Chodakewitz Jeffrey 4

What Happened Jeffrey Chodakewitz, a director of Praxis Precision Medicines (PRAX), received equity awards on June 10, 2026. The filing reports (1) 1,371 restricted stock units (RSUs) and (2) 648 derivative awards, each acquired at $0 (reported as grant/award, code A). These are compensation grants, not open-market purchases or sales, so no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely).
• Reported amounts and price: 1,371 RSUs @ $0; 648 derivative awards @ $0; reported total value $0 (no purchase price).
• Vesting:
  • 1,371 RSUs vest in a single annual installment on the earlier of June 10, 2027 or the 2027 annual meeting (F1). RSUs settle only in shares.
  • 648 derivative awards vest in 12 equal monthly installments starting July 10, 2026 through the earlier of June 10, 2027 or the 2027 annual meeting (F2).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction code: A = award/grant. No 10b5-1 plan, tax-withholding, or late-filing flags disclosed in this filing.

Context These are standard equity compensation grants to a board member and are recorded at $0 because they are awards rather than purchases. RSUs and the listed derivative awards are subject to vesting schedules; they become economically meaningful only as they vest and are settled into shares. Such grants are common for directors and are part of compensation practices rather than direct signals of buying or selling by the insider.